Summary Of Significant Accounting Policies - Addtional Information (Detail) (USD $)	12 Months Ended				80 Months Ended				12 Months Ended							12 Months Ended						80 Months Ended		12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013		Dec. 31, 2011	May 09, 2007	Dec. 31, 2013 Research and Development Expense	Dec. 31, 2013 Warrant	Dec. 31, 2012 Warrant	Dec. 31, 2013 Drug Substance	Dec. 31, 2013 Jp Morgan Chase Bank	Jun. 30, 2012 Md Anderson	Dec. 31, 2011 Md Anderson	Dec. 31, 2013 Md Anderson Research and Development Expense	Dec. 31, 2012 Md Anderson Research and Development Expense	Dec. 31, 2013 Related Party		Dec. 31, 2012 Related Party		Dec. 31, 2013 Related Party		Dec. 31, 2013 Related Party Research and Development Expense	Dec. 31, 2012 Related Party Research and Development Expense
Significant Accounting Policies [Line Items]
Cash paid to MD Anderson Cancer Center for expenses																$ 115,705	$ 463,870
Accrued license payments - related party	100,000		100,000		100,000											100,000
Accrued expense - related party	52,050		26,000		52,050											52,050									26,000
Cash, FDIC insured amount			284,046										3,301,832
Other intangible assets, net	1,411,518		1,572,143		1,411,518
Other finite-lived intangible assets, gross	2,500,374		2,500,374		2,500,374
Amortization of intangible assets	1,088,856		928,231
Technology cost paid in cash														836,207	836,207
Technology cost paid in shares														3,138,889	3,138,889
Technology cost paid in shares value														2,354,167	2,354,167
Technology impairment charge														690,000	690,000
Technology amortization period	15 years
Technology amortization monthly	160,000				160,000
Research and Development	1,518,885	[1]	1,132,712	[1]	5,844,481	[1]						389,911						115,705	[2]	463,870	[2]	1,179,325	[2]	115,705	463,870
Purchase of drug product material	502,940
Product testing and other services cost									185,836
Clinical Trial Expense	85,494															52,050		52,050
Licence Maintenance Fees																50,000								50,000
SIRNA patent technology license																13,655								13,655	8,582
Research and development costs expenses	1,518,885
Federal deposit insurance													250,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,848,298		3,296,354							10,000	10,000
Amortization	160,625		185,271		1,137,359
Equity compensation	32,879
Cash	3,551,832		534,046		3,551,832		952,252	0
License Expenses	63,655															63,655
Annual Maintenance Fee																									100,000
Drug Storage and Transportation									17,897
Advisory Services									$ 79,648

[1] Research and development expense includes stock option expense of $32,879 and $53,645 for the years ending 12/31/2013 and 12/31/2012, respectively; and $455,877 for the period from inception through 12/31/2013. Research and development expense also includes amortization expense of $160,625 and $185,271 for the years ending 12/31/2013 and 12/31/2012, respectively; and $1,137,359 for the period from inception through 12/31/2013.

[2] Includes $345,000 technology impairment charge for the year ending 12/31/2012; and technology impairment of $690,000 for the period from inception through 12/31/2013.